Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep. Watched spongie as well. Kids born in 97&99.
Love plankton
I think it's because they were a 6 $ stock and bought out at such a high premium some took profits off table.
Lol. Me too.
Just heard Cramer say Pfizer will be looking for acquisitions.
Not saying I follow or believe the guy. Just saying.
Yep agreed.
No it is definitely Oct 1987. I was a phone clerk back then for a commodities firm.
Good point City
I hope and think you will be correct.
Wonder if" the law" is sitting back still eating his popcorn
5 million shares per minute being traded
I hear ya. Hopefully we don't drop after the gap up but if we do I think we'll retrace back up. Don't think too many people want to be without over the weekend.
"breakaway gap"?
Looking good with room to move on up
Looking forward to it, thanks Otc!
Lots of talk about our hopeful riches but If this does what we want it to do we need to hoist Koos and the crew on our shoulders and as Bridget says "Champagne" ! for all!
Great day everybody. Congrats!
It is a possibility. But if it does I think it'll retrace its way back up and finish green.
Yeehaw
Gonna be wide open after.. 0325 gets smashed and becomes support
Got to get through. 0325 then yep
May have some resistance near. 0325
Seems like someone is nibbling on the shares causing it to rise.
Though I don't drink it I'll buy and try some Johnny Walker Blue Label
And I agree with you on that.
Yeah the GOOD TO GO sign
I have NEVER in 30 plus years seen a stock with such potential being held down soooo hard as this one.
Tells me something....
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.Press Release | 08/19/2021
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) With much anticipation, Oncology Pharma, Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc. Oncology Pharma will pursue the early feasibility and nonclinical development of a dactinomycin nanoemulsion drug product intended for the treatment of pediatric cancer.
Oncology Pharma is pleased to be moving forward with the development of its first product based upon licensed technology in Oncology Pharma's growing portfolio of licensed intellectual property. Oncology Pharma's agreement with NanoSmart Pharmaceuticals will allow for continued development of a proprietary lead-candidate formulation leading to the submission of an Investigational New Drug application to the US FDA. This phase of cancer drug development is intended to also support potential applications in veterinary oncology.
Oncology Pharma is excited to be combining efforts with NanoSmart Pharmaceuticals to pursue research and develop of improved treatments for pediatric cancers.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the 'Company') is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
ABOUT NANOSMART PHARMACEUTICALS, INC.
NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms, including utilization of anti-nuclear antibody (ANA) to target existing drug therapies to areas of necrosis present in virtually all solid cancer tumors.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships, and costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
website: www.oncology-pharma.com
email: info@oncology-pharma.com
SOURCE: Oncology Pharma Inc.
Nice action so far
A day late
Elgordo es /esta Explosivo?
Definitely
Not saying I want it that way. Want you to be correct.
This may tap into. 026 s. Techs inferring such.
Again, after that consolidation
Like clockwork
Totally agree. All technicals out window with news. No news, then it should consolidate for the next move
1 month macd indicates we could pull back a little
May pull back to there soon and then hopefully move back up or onward.
After that. 025 ish for next level of retrace support. May swoosh down and get that too. Will/should then go back up